Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) recommends the use of Abrysvo™ (respiratory syncytial virus vaccine) for active immunization of pregnant individuals at 32 through 36 weeks gestational age, for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age.
Abrysvo is an unadjuvanted bivalent vaccine containing recombinant RSV prefusion F (preF) A and RSV preF B. The approval for maternal immunization was based on data from the phase 3 MATISSE trial (ClinicalTrials.gov Identifier: NCT04424316).
“This is another new tool we can use this fall and winter to help protect lives,” said CDC Director Dr. Mandy Cohen. “I encourage parents to talk to their doctors about how to protect their little ones against serious RSV illness, using either a vaccine given during pregnancy, or an RSV immunization given to your baby after birth.”
Abrysvo is currently available in a kit containing a vial of lyophilized antigen component, a prefilled syringe containing diluent and a vial adapter. Prior to intramuscular administration, the lyophilized antigen component should be reconstituted with the sterile water diluent component.
Abrysvo is also indicated for the prevention of LRTD caused by RSV in individuals 60 years of age and older.
This article originally appeared on MPR
References:
- Pfizer broadens portfolio of respiratory vaccines recommended by CDC Advisory Committee with Abrysvo™ for RSV. News release. Pfizer Inc. September 22, 2023. Accessed September 25, 2023. https://www.businesswire.com/news/home/20230922409879/en/Pfizer-Broadens-Portfolio-of-Respiratory-Vaccines-Recommended-by-CDC-Advisory-Committee-with-ABRYSVO%E2%84%A2-for-RSV.
- CDC recommends new vaccine to help protect babies against severe respiratory syncytial virus (RSV) illness after birth. News release. Centers for Disease Control and Prevention. September 22, 2023. Accessed September 25, 2023. https://www.cdc.gov/media/releases/2023/p0922-RSV-maternal-vaccine.html.
